Production (Stage)
Beam Therapeutics Inc.
BEAM
$17.31
$0.482.85%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -10.74% | -163.27% | -0.60% | -10.00% | -2.29% |
Total Depreciation and Amortization | 1.79% | 1.51% | 5.55% | 15.78% | 16.87% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | -19.46% | 59.02% | 38.09% | 106.23% | 17.22% |
Change in Net Operating Assets | 32.90% | 34.14% | -30.32% | -26.59% | 15.33% |
Cash from Operations | -4.15% | -156.54% | 1.85% | 1.96% | 9.17% |
Capital Expenditure | -25.72% | 17.25% | 80.16% | 87.88% | 59.48% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -139.14% | 27.10% | 1,251.40% | 453.55% | -262.15% |
Cash from Investing | -133.97% | 28.73% | 341.43% | 310.93% | -310.07% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | 100.00% | 49.75% | 82.66% | 70.65% |
Issuance of Common Stock | 15,299.45% | -89.97% | -96.11% | -99.78% | -96.90% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 16,240.32% | -89.78% | -96.57% | -99.88% | -97.06% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 262.60% | -80.01% | 1.70% | 124.81% | -1,169.70% |